How does hepatitis B virus infection react to hepatocellular carcinoma treatment?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 1, 2012, Pages 1-2

  Wong, Grace L H ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL THERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DISEASE ACTIVITY; EDITORIAL; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT INDICATION; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 84155192670     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06950.x     Document Type: Editorial

References (20)

1. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin. Liver Dis. 2006; 26: 153-61.
2. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
3. Vizzini GB, Luca A, Marino IR. Hepatitis B virus reactivation after a single session of transarterial chemoembolization in patients with hepatocellular carcinoma. Ann. Intern. Med. 2003; 138: 691-2.
4. Jang JW, Choi JY, Bae SH etal. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J. Hepatol. 2004; 41: 427-35.
5. Park JW, Park KW, Cho SH etal. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am. J. Gastroenterol. 2005; 100: 2194-200.
6. Xu J, Wang YH, Xia JL etal. Effect of transcatheter arterial chemoembolization on HBV DNA level in primary liver cancer patients. Chin. J. Cancer 2009; 28: 1-5.
7. Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg. Today 2010; 40: 793-808.
8. Kubo S, Nishiguchi S, Hamba H etal. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann. Surg. 2001; 233: 139-45.
9. Huang L, Li J, Lau WY etal. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2012; 27: 158-64.
10. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J. Gastroenterol. Hepatol. 2011; 26: 628-38.
11. Wong JS, Wong GLH, Tsoi KK etal. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2011; 33: 1104-12.
12. Chuma M, Hige S, Kamiyama T etal. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J. Gastroenterol. 2009; 44: 991-9.
13. Hung IF, Poon RT, Lai CL etal. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am. J. Gastroenterol. 2008; 103: 1663-73.
14. Koda M, Nagahara T, Matono T etal. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern. Med. 2009; 48: 11-17.
15. Kubo S, Tanaka H, Takemura S etal. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol. Res. 2007; 37: 94-100.
16. Kuzuya T, Katano Y, Kumada T etal. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2007; 22: 1929-35.
17. Li N, Lai EC, Shi J etal. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann. Surg. Oncol. 2010; 17: 179-85.
18. Piao CY, Fujioka S, Iwasaki Y etal. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Med. Okayama 2005; 59: 217-24.
19. Shuqun C, Mengchao W, Han C etal. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology 2006; 53: 249-52.
20. Yoshida H, Yoshida H, Goto E etal. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol. Int. 2008; 2: 89-94.